Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

SEC in a publicly accessible document. Clinical program guidance is as of March 17, 2008 and financial guidance relating to the Company's current cash, cash equivalents and investments is as of December 31, 2007.

This press release includes forward-looking statements regarding the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing a product candidate or Alexza's goals, expectations, intentions or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs that are intended to be safe and effective for use as therapeutics. Alexza's forward-looking statements also involve assumptions that, if they do not materialize or prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These statements are based only on facts and factors known by Alexza as of the date hereof. As a result, investors are cautioned not to rely on these forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability." "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations." "Failure or delay in comme
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014   Vittamed Corporation , a ... announced today that T. (Teo) Forcht Dagi , ... company,s Board of Directors. " Teo Forcht ... in neurosurgery, medical innovation and venture capital," said Remis ... delighted to add his clinical, strategic, and entrepreneurial expertise to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... stimulants combined provide greater improvement in symptoms ... Addrenex Pharmaceuticals, Inc. today announced positive results ... Clonicel demonstrating that the combination of Clonicel ... in attention deficit hyperactivity disorder (ADHD) symptoms ...
... After a review of several vendors, the University ... selected the services of Velos and its flagship product, ... implemented at UCLA,s Jonsson Comprehensive Cancer Center and an ... Plans are in place to deploy the system in ...
Cached Medicine Technology:Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication 2University of California Los Angeles Selects Velos eResearch 2University of California Los Angeles Selects Velos eResearch 3University of California Los Angeles Selects Velos eResearch 4University of California Los Angeles Selects Velos eResearch 5University of California Los Angeles Selects Velos eResearch 6
(Date:8/29/2014)... (HealthDay News) -- The West African Ebola outbreak took a ... an estimated 500 new cases this week -- the biggest ... cases arose in Liberia, the U.N. health agency said, but ... Associated Press reported. "There are serious problems ... the WHO report. "The situation is worsening in Liberia and ...
(Date:8/29/2014)... September yoga month was created by the Yoga Health ... benefits. To support this Ekhart Yoga is offering those ... , This 4 week guided online yoga program is ... yoga regularly from their own home. Led by Esther ... for all levels, and the dynamic classes will help ...
(Date:8/29/2014)... RBS Reputation Management has brought a new ... service is to help those individuals and organizations that are ... Book. The service would push down the ranking of Scam ... fully invisible on Google. , RBS Reputation Management provides ... asked how company can provide guarantee of results with the ...
(Date:8/29/2014)... Last week, the Fed reported an increase ... production rose to 0.4% while manufacturing output progressed to 1.0%. ... largest boost since February this year. Capacity use has increased ... well – an increase that could be attributed to the ... rate, which is a measure of slack across the industries. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Ethane Web ... recently launched a new service named HTML web design. ... based service. Before tailoring the service, Ethane Web Technologies ... other companies. The company has done its best efforts ... and able to deliver outstanding results to clients. ...
Breaking Medicine News(10 mins):Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 3Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Ethane Web Technologies Launches a New Web Design Service 2
... that the usage of aspirin to prevent heart problem have ... of Pittsburgh Graduate School of Public Health (GSPH) and others ... Medicine. It said that African Americans and diabetics do not ... medical centers of US and Europe measured regular use of ...
... conducted by Jerald Greenberg professor of management and human resources ... that pay cuts resulted in loss of money and sleep ... in different cities in the Northeast. ,In these ... salary by 10%. The author conducted a supervisor training in ...
... Derek Griffiths, Ph.D., professor of geriatric medicine, University of Pittsburgh ... to the reduced activity of the orbitofrontal cortex of the ... recent issue of the Journal of Urology. He studied the ... , He analyzed the brain activity of 6 normal people ...
... was stated that Malaria affects 300 to 500 million people ... leading// cause of illness and death in the sub-Saharan African ... the Uganda Malaria Surveillance Project and Julia Critchley of the ... drugs showed better efficiency when used in the treatment of ...
... the number of breast cancer cases in the UK. As ... with the ductal carcinoma// in situ (DCIS) during 2002. The ... the hormone therapy drugs are capable of preventing the recurrence ... anastrozole are being studied. The DCIS is considered a pre-cancerous ...
... with regard to a ten-year-old plan to scale down the ... and the rich with regard to this however remains unchanged. ... the establishment of 34 networks for providing better treatment. As ... ,Improvements have been made with regard to ...
Cached Medicine News:Health News:Pay Cut Leads To Increased Levels Of Insomnia Among Workers 2Health News:Older Malarial Drugs Vs New Ones 2
... be used only with the E3671 twisted snare ... the wing nut and the loop can be ... ratchet so that the loop can be slipped ... length - 5.6 inches. Comes with one package ...
Open 14 mm fixation ring with teeth to prevent damage to conjuctiva. Gauge is marked every 10 degrees to determine the extent of the arc to be incised. Two broad marks align with steep axis....
... Titanium. Designed to fixate the ... The two-sided ring can easily ... pointed or smooth side on ... pressure to the eye to ...
For sterilizing, carrying and storage of a Storz diamond knife and barrel gauge....
Medicine Products: